Adam D. Cohen, MD, is the Director of Myeloma Immunotherapy, Amyloidosis Program Co-Director, and Associate Professor of Medicine at the Abramson Cancer Center at the University of Pennsylvania. His research focuses on clinical development of novel therapies, particularly immunotherapies, for patients with myeloma, AL amyloidosis and other plasma cell dyscrasias. Dr Cohen's attendance is kindly sponsored by Janssen

Dr Anderson graduated from Medicine at the University of Melbourne in 2003. She trained in general medicine and haematology at the Royal Melbourne Hospital and the Alfred Hospital obtaining her fellowships with the Royal Australian College of Physicians and the Royal College of Pathologists of Australasia in 2011. After completion of her clinical training in haematology Dr Anderson undertook a translational PhD through the Walter and Eliza Hall Institute. Dr Anderson’s PhD studies focused on the clinical implementation of venetoclax in the phase I first in human trial of the agent in patients with chronic lymphocytic leukemia. Since 2017 Dr Anderson has held a postdoctoral research position at the Walter and Eliza Hall Institute where her research focuses on resistance mechanisms of lymphomas and leukemias to novel agent therapy.

Professor Curtis is a Clinical Haematologist and Director of Malignant Haematology Research at the Australian Centre for Blood Diseases, Monash University, Alfred Hospital. He is a senior bone marrow transplant physician at Alfred Health, where he is leading a national randomised trial of post-transplant cyclophosphamide for the prevention of graft versus host disease, a life-threatening complication following bone marrow transplant. His research focuses on understanding how normal blood stem cells develop into leukaemia and how these abnormal leukaemia stem cells can survive high dose treatments including chemotherapy and bone marrow transplant. Professor Curtis has attracted over $20 million in research funds including funding for National Centre of Research Excellence for Blood and Cell Therapies, with the goal of increasing clinical trials for improving outcomes for patients having bone marrow transplants and training for the next generation of physician scientists.